SCHEMBL4675221

SCHEMBL4675221

Cc1oc(C(=O)C=C(O)c2nc[nH]n2)cc1Cc1ccncc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.34
LMNA P02545 2/20 0.34
POLB P06746 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PDE3B Q13370 1/20 0.33
PDE3A Q14432 1/20 0.33
PTGER4 P35408 10/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 4/20 0.33
NPC1 O15118 1/20 0.32
APEX1 P27695 1/20 0.32
RECQL P46063 1/20 0.32
MAPT P10636 1/20 0.31
RXRA P19793 1/20 0.31
PIM1 P11309 1/20 0.31
PIM2 Q9P1W9 1/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672620 0.88 SNCA (0.33) LMNAPDE3BPDE3APIM1PIM2
SCHEMBL5899383 0.88 PIM1 (0.31) PIM1PIM2
SCHEMBL4674887 0.85 ALDH1A1 (0.33) KDM4ELMNAPOLBTDP1PDE3B
SCHEMBL4674842 0.84 PDE3B (0.33) KDM4ELMNAPDE3BPDE3AALDH1A1
SCHEMBL4678767 0.84 CYP19A1 (0.36) KDM4ELMNAALDH1A1HPGDPIM1
SCHEMBL4677384 0.82 POLB (0.35) KDM4ELMNAPOLBHSD17B10TDP1
SCHEMBL4675411 0.82 CYP11B1 (0.33) LMNAPDE3BPDE3AALDH1A1HPGD
SCHEMBL4671265 0.81 ABCB1 (0.35) KDM4EPIM1PIM2
SCHEMBL4673166 0.81 PIM1 (0.31) PIM1PIM2
SCHEMBL4675299 0.81 PIM1 (0.33) KDM4ELMNAL3MBTL1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KDM4E 947/4885LMNA 659/4885POLB 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.